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ABSTRACT 
 
Introduction: To estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC 
(PSMA-11). Methods: Under an RDRC-approved research protocol, we evaluated the 
biodistribution and pharmacokinetics of [68Ga]Ga-HBED-CC (PSMA-11)  with serial PET 
imaging following intravenous administration to nine prostate cancer patients in whom 
clinical [11C]acetate PET/CT exams had been independently performed under Expanded 
Access IND 118,204. List-mode imaging was performed over the initial 0-10 minutes 
post-injection with the pelvis in the field-of-view. Whole-body images were acquired, 
pelvis-to-head, at 15, 60, and 90-minutes post-injection. Additional images of the pelvis 
were acquired at 40-minutes and 115-minutes, and voided urine collected from each 
subject at 48-minutes and 120-minutes post-injection.  Radiation dosimetry estimates 
were calculated from these data using the OLINDA software package. Results: Renal 
uptake was high and relatively invariant, ranging from 11% to 14% of the injected dose 
between 15 and 90-minutes post-injection. Radioactivity collected in the voided urine 
accounted for 14% of the injected dose over a period of 120-minutes. Lymph nodes and 
skeletal metastases suspicious for prostate cancer recurrence were detected in fewer 
patients using 11C-acetate than using [68Ga]Ga-HBED-CC (PSMA-11).  Conclusion: 
Kidneys are the critical organ following [68Ga]Ga-HBED-CC (PSMA-11)  administration, 
receiving an estimated dose of 0.413 mGy/MBq. Advances in Knowledge and 
Implications for Patient Care: This study confirms that the kidneys will be the critical 
organ following intravenous administration of [68Ga]Ga-HBED-CC (PSMA-11), and 
provided data consistent with the expectation that [68Ga]Ga-HBED-CC (PSMA-11)  will 
be superior to [11C]acetate for defining sites of recurrence in prostate cancer patients 
presenting with biochemical relapse. 
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Introduction 
 
The PSMA-targeted [68Ga]Ga-HBED-CC (PSMA-11) radiopharmaceutical has been 
shown to be quite useful in imaging patients with prostate cancer to define the location 
and extent of disease [1-2]. However, despite its fairly extensive human use of [68Ga]Ga-
HBED-CC, until recently no estimates of the human radiation dosimetry for [68Ga]Ga-
HBED-CC were available in the published literature. Those recently published data [3,4] 
represent findings in a very limited number of subjects, in one case only four subjects 
[3], and the other case, five subjects who received a concurrent dosing with furosemide 
[4]. To Independently assess [68Ga]Ga-HBED-CC (PSMA-11) dosimetry, we have 
evaluated the radiopharmaceutical’s biodistribution and pharmacokinetics with serial 
PET imaging following intravenous administration to nine prostate cancer patients in 
whom 11C-acetate PET/CT exams had been clinically performed under Expanded 
Access IND 118,204 to assess disease recurrence. 
 
 
Materials and Methods 
 
Our use of [68Ga]Ga-HBED-CC (PSMA-11) in PET/CT imaging was reviewed and 
approved by the Indiana University Radioactive Drug Research Committee and the 
Indiana University Institutional Review Board (IRB). Subjects were recruited from 
patients undergoing clinical imaging with 11C-acetate (Expanded Access IND 118,204) 
due to suspected recurrence of prostate cancer that had previously been treated with 
surgery or radiation therapy (i.e., all subjects were prostate cancer patients presenting 
with “biochemical failure”). All subjects provided written informed consent prior to 
4 
administration of the [68Ga]Ga-HBED-CC radiopharmaceutical. The interval between 
[11C]acetate and [68Ga]Ga-HBED-CC PET/CT imaging averaged 21 ± 25 days 
(median 20 days; range 0-83 days). The reported serum PSA levels 
(Supplemental Data) were the most recent clinical values at the time of 68Ga 
imaging, obtained an average of 61 ± 41 days prior to the [68Ga]Ga-HBED-CC 
study (median 42 days; range 33-157 days). 
 
Radiochemistry 
The HBED-CC (PSMA-11) conjugate was purchased from ABX GmbH as commercial 
cGMP-grade product packaged at 10-µg per vial.  The [68Ga]Ga-HBED-CC (PSMA-11) 
radiopharmaceutical was prepared using 68Ga from ITG Isotope Technologies Garching 
GmbH 68Ge/68Ga generators (30-mCi; 1.11 GBq). Briefly, the 4.0-mL 0.05M ultrapure 
HCl generator eluate was buffered to pH ~4.8 by addition of ultrapure NaOAc and 
reacted with the HBED-CC conjugate (10-µg) with heating at ~95°C for 5-minutes 
employing ITG’s manually controlled iQS® Ga-68 Fluidic Labeling Module [5-8]. The 
complete synthetic protocol was as we have described for [68Ga]Ga-DOTA-NOC, with 
the exceptions of using only a 5-minute reaction time, and the substitution of HBED-CC 
(PSMA-11) for DOTA-NOC [5]. Pre-release product quality control procedures included: 
half-life measurement for confirmation of radionuclidic identity; pH measurement; ITLC 
assessment of radiochemical purity; endotoxin testing; and a bubble point measurement 
to confirm the integrity of the single-use sterile 0.2-µm filter employed for terminal 
product sterilization. The ITLC determination of radiochemical purity employed ITLC-SG 
strips developed with 1:1 MeOH:1M NH4OAc to quantify colloidal 68Ga-hydroxide plus 
ionic 68Ga, both of which remain at or near the origin while the [68Ga]Ga-HBED-CC 
product migrates near the solvent front. Retrospective analysis of each production batch 
5 
included sterility testing, and measurement of 68Ge breakthrough levels in the final 
product [5].  
 
PET/CT Imaging and Image Analysis   
Imaging was performed using a Siemens mCT extended FOV time-of-flight PET/CT (128 
slice) camera. Following a low-dose pelvis-to-head CT scan for attenuation correction, 
the radiopharmaceutical was administered intravenously with the patient’s pelvis in the 
PET field-of-view for a list-mode acquisition from 0-10 minutes, followed by a whole-
body (pelvis to head) PET acquisition starting at 15-minutes post-injection. An image of 
the pelvis was again collected at 40-minutes, then the patient removed from the camera 
and urine collected. The patient then returned to the PET/CT camera for a second low-
dose (attenuation correction only) CT scan, followed by whole-body (pelvis-to-head) PET 
acquisitions at 60-minutes and 90-minutes, with a final PET image of the pelvis collected 
at 115 minutes. Again the patient was removed from the camera and directed to void his 
bladder with collection of the excreted urine. The volume of the collected urine samples 
was measured, and the excreted radioactivity quantified by dose calibrator assay of a 
20-mL sample.  PET images were reconstructed using both filtered back-projection 
(FBP), and a standard clinical iterative algorithm,  (3 iterations and 21 subsets); 3-D 
volumes-of-interest were drawn for the tissues of interest using the MIM PET Edge 
(v6.5) software package, and corresponding SUVmean values extracted for calculation of 
radiopharmaceutical biodistribution as a percentage of the injected dose per tissue. 
Iterative vs. FBP reconstruction provided comparable SUVmean values; the reported 
results (Table 1) are from the iterative reconstructions.  
 
Radiation dosimetry estimates (Table 2) were obtained from the PET/CT biodistribution 
data (Table 1) using the OLINDA software package (Organ level Internal Dose 
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Assessment Code, Vanderbilt University, 2003). For these dose estimates, it was 
assumed that the urinary bladder was completely voided at 120-minutes post-injection, 
and that over the first 120-minutes the bladder contained the cumulative measured urine 
levels of radioactivity without intermediate voiding. The remaining unspecified 
radioactivity was assumed to be uniformly distributed in the remaining body volume.  
 
 
Results and Discussion 
 
The [68Ga]Ga-HBED-CC (PSMA-11) radiopharmaceutical has been shown to be useful 
in the detection of tumor recurrence in prostate cancer patients previously treated with 
prostatectomy or radiation therapy [1,2], with lesion detectability appearing to be better 
than we can achieve with [11C]acetate PET/CT. [68Ga]Ga-HBED-CC (PSMA-11) has a 
relatively low molecular weight (1014 g/mole), and targets the cell surface prostate-
specific membrane antigen (PSMA) with the urea fragment of the Glu-urea-Lys(Ahx)-
HBED-CC conjugate [9]. The 68Ga3+ ion is bound with high affinity in an octahedral N2O4
 
coordination sphere by the two phenolate O, two amino-acetate carboxylate O, and the 
two amino N donor atoms of the HBED chelator [9-12].  
 
Radiochemical purity of the [68Ga]Ga-HBED-CC (PSMA-11) averaged 98.9 ± 0.5% (n = 
9), with 68Ge breakthrough levels in the final product averaging 8.5 x 10-6 ± 7.9 x 10-6% 
(calculated for the time of dose expiration). Synthesis time, beginning-of-elution to dose 
release, averaged 42 ± 1 minutes. Patients reported no symptoms, nor exhibited any 
adverse reactions, following radiopharmaceutical administration (3.04 ± 0.09 mCi, 112.5 
± 3.3 MBq). The administered mass of the HBED-CC (PSMA-11) ligand averaged 3.2 ± 
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0.4 µg, assuming all the HBED-CC (PSMA-11) in the reaction mixture remained present 
in the final product solution.  
 
The PET/CT biodistribution findings for [68Ga]Ga-HBED-CC are shown in Table 1, with a 
patient-by-patient tabulation provided in the Supplemental Data. Observed SUVmean 
values at 60-minutes for kidneys, liver, spleen, and parotids (30.1 ± 6.6; 3.3 ± 0.6; 5.2 ± 
2.5; and 9.4 ± 2.0, respectively) are in general agreement with the SUV values of 31.7; 
5.1; 7.2; and 12.9 reported by Dietlein, et al. [13].  
 
Radiation dosimetry estimates, calculated from the Table 1 data using the OLINDA 
software package, are shown in Table 2. The kidneys are the critical organ, with an 
absorbed dose of 0.413 mGy/MBq (1.53 Rad/mCi).  The total body dose is estimated to 
be 0.0143 mGy/MBq (0.0529 Rad/mCi), with an effective dose equivalent of 0.044 
mSv/MBq (0.163 Rad/mCi).  Afshar-Oromich, et al. [3] similarly conclude that the 
kidneys are the critical organ, arriving at an estimated renal dose of 0.26 mGy/MBq in 
their study of four subjects that included additional renal clearance data between 2 and 5 
hours. Differences in administered mass of PSMA-11 may also result in some changes 
in renal retention of the radiotracer, but are not possible to directly compare from the 
published data [3]. Pfob, et al. [4], report a renal adsorbed dose of only 0.121 mGy/MBq, 
but those data are not directly comparable, since that study was performed with 
concurrent administration of furosemide at an unspecified dose to promote urine 
production and urinary clearance.  
 
Comparison of images obtained with [68Ga]Ga-HBED-CC and 11C-acetate demonstrated 
enhanced 68Ga identification of lymph nodes and skeletal lesions suspicious for 
metastatic recurrent prostate cancer, supporting clinical use of [68Ga]Ga-HBED-CC 
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(PSMA-11) as an alternative to [11C]acetate in assessment of prostate cancer patients 
presenting with biochemical failure. As examples, Figures 1 and 2 illustrate these 
findings in two of the subjects.  While this comparison was not the study objective, and 
the sample size is small, our results favor clinical use of [68Ga]Ga-HBED-CC (PSMA-11) 
over [11C]acetate, as would be expected based on the reported clinical experience with 
[68Ga]Ga-HBED-CC (PSMA-11) [1,2]. 
 
Conclusions 
Radiation dosimetry estimates were calculated for [68Ga]Ga-HBED-CC (PSMA-11) 
from nine prostate cancer patients in whom clinical [11C]acetate PET/CT exams had 
been previously performed under Expanded Access IND118,204. Kidneys are the critical 
organ following [68Ga]Ga-HBED-CC (PSMA-11) administration, receiving an estimated 
dose of 0.413 mGy/MBq.   
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Supplemental Data 
A patient-by-patient tabulation of the biodistribution findings, and complete OLINDA 
output, is available in the online publication. 
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Table 1. Observed Biodistribution of 68Ga Following Intravenous Administration of 68Ga-HBED-CC (PSMA-11) (3.04 ± 0.09 
mCi, 112.5 ± 3.3 MBq; Injected HBED-CC = 3.2 ± 0.4 µg) to Adult Males (95.8 ± 20.3 kg) Previously Treated for Prostate 
Cancer and Presenting with Biochemical Failure  
(average serum PSA value of 2.3 ± 3.8 ng/mL; range 0.16 – 11.3 ng/mL; median 0.52 ng/mL).  
 
Tissue Uptake of 68Ga as a Percentage of Injected Dose (± Std. Dev.; n = 9)  
15 Minutes 40 Minutes 48 Minutes 60 Minutes 90 Minutes 115 Minutes 120 Minutes 
Lacrimal Glands 
(L + R) 
0.0090 ± 
0.0044 
  0.0066 ± 
0.0050 
0.0075 ± 
0.0049 
  
Parotid Glands 
(L + R) 0.79 ± 0.26 
  
0.87 ± 0.30 0.92 ± 0.35 
  
Submandibular 
Glands (L + R) 0.25 ± 0.15 
  
0.29 ± 0.19 0.30 ± 0.19 
  
Liver 9.24  ± 2.14   6.54 ± 1.43 5.98 ± 1.39   
Kidneys (L + R) 11.23 ± 2.20   14.02 ± 3.73 14.21 ± 4.54   
Spleen 1.64 ± 0.80   1.25 ± 0.63 1.06 ± 0.55   
Pancreas 0.12 ± 0.07   0.091 ± 0.064 0.086 ± 0.063   
Urinary bladder 0.85 ± 0.36 2.84 ± 1.04  1.22 ± 0.49 2.97 ± 1.32 6.53 ± 1.83  
Voided Urine   4.18 ± 1.68    9.43 ± 2.55 
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Table 2. Radiation Dosimetry Estimates* for [68Ga]Ga-HBED-CC (PSMA-11) 
 
Target Organ Organ Doses (rem/mCi) Organ Doses (mSv/MBq) 
Adrenals 6.42E-02 1.74E-02 
Brain 3.72E-02 1.01E-02 
Breasts 3.74E-02 1.01E-02 
Gallbladder Wall 6.06E-02 1.64E-02 
LLI Wall 4.70E-02 1.27E-02 
Small Intestine 5.07E-02 1.37E-02 
Stomach Wall 5.05E-02 1.37E-02 
ULI Wall 5.04E-02 1.36E-02 
Heart Wall 4.60E-02 1.24E-02 
Kidneys 1.53E+00 4.13E-01 
Liver 1.46E-01 3.95E-02 
Lungs 4.29E-02 1.16E-02 
Muscle 4.29E-02 1.16E-02 
Pancreas 7.35E-02 1.99E-02 
Red Marrow 3.80E-02 1.03E-02 
Osteogenic Cells 5.06E-02 1.37E-02 
Skin 3.67E-02 9.93E-03 
Spleen 2.15E-01 5.81E-02 
Testes 4.07E-02 1.10E-02 
Thymus 4.13E-02 1.12E-02 
Thyroid 4.04E-02 1.09E-02 
Urinary Bladder Wall 2.48E-01 6.71E-02 
Total Body 5.29E-02 1.43E-02 
   
Effective Dose Equivalent 1.63E-01 4.40E-02 
Effective Dose 9.53E-02 2.58E-02 
 
*Calculated with OLINDA using the biodistribution data for the nine male subjects 
reported in Table 1, assuming no voiding of the urinary bladder until 2-hours post-
injection. 
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Figure 1.  Example of PET images (right) and fused PET/CT images (left) 
obtained with 68Ga-HBED-CC (PSMA-11) (top) and 11C-acetate (bottom).  The 11C 
acetate image was obtained 48-days prior to 68Ga imaging. Serum PSA was 1.7 ng/mL 
at the time of the acetate study. The red arrows indicates PSMA-avid retroperitoneal 
lymph nodes that are not acetate-avid (yellow arrows).  The acetate PET image was 
reconstructed from data collected at 10 minutes post-injection. The 68Ga image was 
reconstructed from data collected at 15 minutes post-injection. Lymph node 
uptake in the 68Ga-images showed slight increase with time (SUVmean values of 
6.0, 7.8, and 8.8 (lymph node A) and 5.3, 7.3 and 9.6 (lymph node B) in images 
collected at 15, 60, and 90-minutes post-injection, respectively).  
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Figure 2. Additional example of PET images (right) and fused PET/CT images (left) 
obtained with 68Ga-HBED-CC (PSMA-11) (top) and 11C-acetate (bottom).  The 11C 
acetate image was obtained 23-days prior to 68Ga imaging. Serum PSA was 11.1 ng/mL 
at the time of the acetate study. Red arrow indicates PSMA-avid bone metastasis in right 
ilium that was not seen on the 11C-acetate exam. Ureters are noted on the PSMA study.  
The acetate image was reconstructed from data collected at 10 minutes post-injection, 
and the 68Ga image reconstructed from data collected at 15 minutes  post-
injection. Tumor uptake in the 68Ga-images was again relatively invariant with 
time (SUVmean values of 3.5, 3.7, 3.9, 2.4,1.8,1.7,1.7 and 2.2 in images collected 
at  0-3, 4-6, 7-9, 15, 40, 60, 90, and 115-minutes post-injection, respectively).  
 
 
Time	Post-
Injec/on	
(min)
Pa/ent	1 Pa/ent	2 Pa/ent	3 Pa/ent	4 Pa/ent	5 Pa/ent	6 Pa/ent	7 Pa/ent	8 Pa/ent	9 Mean Std	Dev
Injected	Dose	(mCi) 3.18 3.12 2.94 2.95 2.94 3.06 3.01 3.07 3.13 3.04 0.09
Injected	HBED-CC	(µg) 2.82 3.45 3.36 3 3.09 3.27 3.55 3.73 2.36 3.18 0.42
Serum	PSA	(ng/mL) 0.3 0.3 0.52 1.7 11.3 5.5 0.33 0.16 0.65 2.31 3.77
Pa/ent	Body	Mass	(kg) 97.7 106.1 118 122.6 70.05 81.65 112.49 68.94 84.5 95.78 20.35
R	lacrimal 15 0.001 0.003 0.007 0.006 0.006 0.003 0.008 0.002 0.005 0.005 0.002
L	lacrimal 15 0.002 0.001 0.005 0.007 0.005 0.004 0.007 0.002 0.005 0.004 0.002
TOTAL	Lacrimal 15 0.003 0.004 0.012 0.013 0.011 0.007 0.015 0.005 0.011 0.0090 0.0044
R	paro7d 15 0.400 0.264 0.422 0.707 0.297 0.636 0.298 0.217 0.292 0.39 0.17
L	paro7d 15 0.343 0.298 0.477 0.564 0.240 0.478 0.377 0.390 0.404 0.40 0.10
TOTAL	Paro/d 15 0.743 0.562 0.899 1.271 0.537 1.115 0.675 0.607 0.696 0.79 0.26
R	submandibular 15 0.090 0.256 0.089 0.223 0.103 0.104 0.177 0.000 0.080 0.12 0.08
L	submandibular 15 0.088 0.204 0.085 0.226 0.132 0.088 0.215 0.024 0.099 0.13 0.07
TOTAL	Submandibular 15 0.178 0.460 0.174 0.449 0.235 0.191 0.392 0.024 0.179 0.25 0.15
Liver 15 10.045 9.431 7.729 8.382 7.854 13.670 6.116 9.372 10.544 9.24 2.14
R	kidney 15 5.611 5.626 4.561 3.808 6.361 5.539 6.023 7.109 6.505 5.68 1.01
L	kidney 15 5.388 6.090 3.821 3.684 6.104 4.939 5.843 7.066 7.028 5.55 1.23
TOTAL		Kidney 15 11.000 11.716 8.381 7.491 12.465 10.478 11.866 14.175 13.533 11.23 2.20
Spleen 15 0.744 1.395 1.265 1.255 2.641 2.579 2.064 2.331 0.457 1.64 0.80
Pancreas 15 0.203 0.260 0.041 0.081 0.088 0.145 0.084 0.094 0.046 0.12 0.07
Urinary	bladder 15 0.857 0.746 0.844 1.320 1.120 0.463 1.390 0.572 0.375 0.85 0.36
R	lacrimal 60 0.001 0.002 0.003 0.001 0.007 0.003 0.008 0.003 0.001 0.003 0.003
L	lacrimal 60 0.001 0.002 0.001 0.002 0.007 0.005 0.008 0.002 0.001 0.003 0.002
TOTAL	Lacrimal 60 0.002 0.004 0.004 0.003 0.014 0.008 0.016 0.006 0.002 0.0066 0.0050
R	paro7d 60 0.414 0.274 0.403 0.764 0.361 0.756 0.331 0.276 0.244 0.42 0.20
L	paro7d 60 0.298 0.407 0.493 0.689 0.285 0.544 0.517 0.346 0.456 0.45 0.13
TOTAL	Paro/d 60 0.712 0.682 0.896 1.453 0.646 1.300 0.848 0.622 0.700 0.87 0.30
R	submandibular 60 0.099 0.293 0.079 0.243 0.120 0.118 0.240 0.000 0.070 0.14 0.10
L	submandibular 60 0.073 0.232 0.089 0.264 0.167 0.104 0.282 0.021 0.101 0.15 0.09
TOTAL	Submandibular 60 0.173 0.525 0.168 0.507 0.288 0.222 0.523 0.021 0.171 0.29 0.19
Liver 60 6.914 5.992 5.999 6.320 5.920 7.876 3.695 7.584 8.598 6.54 1.43
R	kidney 60 7.094 6.837 5.441 4.376 7.704 7.400 6.155 10.116 9.401 7.17 1.80
L	kidney 60 6.820 7.552 4.238 4.106 7.322 6.694 5.849 9.754 9.350 6.85 1.96
TOTAL		Kidney 60 13.914 14.390 9.679 8.482 15.027 14.094 12.003 19.870 18.751 14.02 3.73
Spleen 60 0.517 1.014 1.000 1.043 2.097 1.741 1.509 1.999 0.321 1.25 0.63
Pancreas 60 0.217 0.165 0.027 0.062 0.064 0.108 0.026 0.097 0.050 0.091 0.064
Urinary	bladder 60 1.396 1.464 0.780 1.464 2.206 0.892 1.312 0.758 0.662 1.22 0.49
R	lacrimal 90 0.001 0.002 0.001 0.002 0.006 0.004 0.009 0.004 0.005 0.004 0.0025
L	lacrimal 90 0.002 0.001 0.001 0.004 0.006 0.005 0.009 0.002 0.005 0.004 0.0025
TOTAL	Lacrimal 90 0.003 0.003 0.002 0.006 0.012 0.008 0.017 0.006 0.011 0.008 0.005
R	paro7d 90 0.425 0.326 0.428 0.923 0.371 0.789 0.331 0.292 0.300 0.46 0.23
L	paro7d 90 0.313 0.389 0.387 0.732 0.280 0.588 0.544 0.336 0.524 0.45 0.15
TOTAL	Paro/d 90 0.738 0.715 0.815 1.655 0.651 1.377 0.875 0.628 0.824 0.92 0.35
R	submandibular 90 0.102 0.305 0.072 0.271 0.114 0.129 0.251 0.001 0.080 0.15 0.10
L	submandibular 90 0.095 0.199 0.077 0.275 0.167 0.107 0.306 0.020 0.111 0.15 0.09
TOTAL	Submandibular 90 0.197 0.503 0.148 0.546 0.281 0.236 0.557 0.020 0.191 0.30 0.19
Liver 90 6.208 5.369 5.686 5.588 5.506 6.619 3.384 6.947 8.524 5.98 1.39
R	kidney 90 7.098 6.773 5.439 4.114 7.581 7.265 5.572 10.905 10.235 7.22 2.20
L	kidney 90 6.949 7.459 4.052 3.909 7.224 7.035 5.339 10.668 10.234 6.99 2.38
TOTAL		Kidney 90 14.047 14.232 9.491 8.023 14.805 14.300 10.911 21.574 20.468 14.21 4.54
Spleen 90 0.422 0.857 0.802 0.885 1.860 1.402 1.357 1.709 0.282 1.06 0.55
Pancreas 90 0.217 0.142 0.024 0.052 0.057 0.092 0.023 0.112 0.054 0.086 0.063
Urinary	bladder 90 3.083 4.362 1.097 2.003 4.811 3.058 4.383 1.773 2.120 2.97 1.32
Urinary	Bladder	 40 2.49 2.77 3.64 3.59 3.53 2.11 4.43 1.17 1.83 2.84 1.04
Urinary	Bladder 115 8.12 7.16 6.15 5.82 7.81 4.78 8.80 2.92 7.20 6.53 1.83
Voided	Urine 48 4.7 4.4 5.5 5.2 5.4 2.1 6.2 1.5 2.6 4.18 1.68
Voided	Urine	 120 10.6 10.5 11.1 9 10.6 6.4 12.5 4.3 9.9 9.43 2.55
Observed	Distribu/on	of	68Ga	by	PET/CT	Following	Intravenous	Administra/on	of	68Ga-HBED-CC	(PSMA-11)	(%	Injected	Dose	per	Organ	or	Tissue)
    OLINDA - Organ Level INternal Dose Assessment Code (copyright Vanderbilt University, 2003)
NOTE: This code gives doses for stylized models of average individuals - 
      results should be applied with caution to specific human subjects.
NOTE: Users should always carefully check input data (shown below) and
      critically review the reported results.
Organ Doses (mSv/MBq), Nuclide: Ga-68 (6.76E01 min), Adult Male
Target Organ                Alpha     Beta     Photon     Total          EDE Cont.  ED Cont.
Adrenals                   0.00E000  7.18E-03  1.02E-02  1.74E-02        0.00E000   4.34E-05
Brain                      0.00E000  7.18E-03  2.88E-03  1.01E-02        0.00E000   2.52E-05
Breasts                    0.00E000  7.18E-03  2.94E-03  1.01E-02        1.52E-03   5.06E-04
Gallbladder Wall           0.00E000  7.18E-03  9.20E-03  1.64E-02        0.00E000   0.00E000
LLI Wall                   0.00E000  7.18E-03  5.52E-03  1.27E-02        0.00E000   1.52E-03
Small Intestine            0.00E000  7.18E-03  6.52E-03  1.37E-02        0.00E000   3.42E-05
Stomach Wall               0.00E000  7.18E-03  6.48E-03  1.37E-02        0.00E000   1.64E-03
ULI Wall                   0.00E000  7.18E-03  6.44E-03  1.36E-02        0.00E000   3.41E-05
Heart Wall                 0.00E000  7.18E-03  5.26E-03  1.24E-02        0.00E000   0.00E000
Kidneys                    0.00E000  3.72E-01  4.04E-02  4.13E-01        2.48E-02   1.03E-02
Liver                      0.00E000  2.91E-02  1.05E-02  3.95E-02        2.37E-03   1.98E-03
Lungs                      0.00E000  7.18E-03  4.42E-03  1.16E-02        1.39E-03   1.39E-03
Muscle                     0.00E000  7.18E-03  4.42E-03  1.16E-02        0.00E000   2.90E-05
Ovaries                    0.00E000  7.18E-03  5.86E-03  1.30E-02        3.26E-03   2.61E-03
Pancreas                   0.00E000  1.04E-02  9.49E-03  1.99E-02        1.19E-03   4.97E-05
Red Marrow                 0.00E000  4.91E-03  5.35E-03  1.03E-02        1.23E-03   1.23E-03
Osteogenic Cells           0.00E000  8.82E-03  4.86E-03  1.37E-02        4.10E-04   1.37E-04
Skin                       0.00E000  7.18E-03  2.75E-03  9.93E-03        0.00E000   9.93E-05
Spleen                     0.00E000  4.55E-02  1.26E-02  5.81E-02        3.49E-03   1.45E-04
Testes                     0.00E000  7.18E-03  3.82E-03  1.10E-02        0.00E000   0.00E000
Thymus                     0.00E000  7.18E-03  3.99E-03  1.12E-02        0.00E000   2.79E-05
Thyroid                    0.00E000  7.18E-03  3.73E-03  1.09E-02        3.27E-04   5.46E-04
Urinary Bladder Wall       0.00E000  5.63E-02  1.08E-02  6.71E-02        4.03E-03   3.35E-03
Uterus                     0.00E000  7.18E-03  6.60E-03  1.38E-02        0.00E000   3.45E-05
Total Body                 0.00E000  9.64E-03  4.65E-03  1.43E-02        0.00E000   0.00E000
Effective Dose Equivalent (mSv/MBq)                                      4.40E-02
Effective Dose (mSv/MBq)                                                            2.58E-02
Organ Doses (rem/mCi), Nuclide: Ga-68 (6.76E01 min), Adult Male
Target Organ                Alpha     Beta     Photon     Total          EDE Cont.  ED Cont.
Adrenals                   0.00E000  2.66E-02  3.76E-02  6.42E-02        0.00E000   1.61E-04
Brain                      0.00E000  2.66E-02  1.07E-02  3.72E-02        0.00E000   9.31E-05
Breasts                    0.00E000  2.66E-02  1.09E-02  3.74E-02        5.62E-03   1.87E-03
Gallbladder Wall           0.00E000  2.66E-02  3.41E-02  6.06E-02        0.00E000   0.00E000
LLI Wall                   0.00E000  2.66E-02  2.04E-02  4.70E-02        0.00E000   5.64E-03
Small Intestine            0.00E000  2.66E-02  2.41E-02  5.07E-02        0.00E000   1.27E-04
Stomach Wall               0.00E000  2.66E-02  2.40E-02  5.05E-02        0.00E000   6.06E-03
ULI Wall                   0.00E000  2.66E-02  2.38E-02  5.04E-02        0.00E000   1.26E-04
Heart Wall                 0.00E000  2.66E-02  1.95E-02  4.60E-02        0.00E000   0.00E000
Kidneys                    0.00E000  1.38E000  1.50E-01  1.53E000        9.16E-02   3.82E-02
Liver                      0.00E000  1.07E-01  3.87E-02  1.46E-01        8.77E-03   7.31E-03
Lungs                      0.00E000  2.66E-02  1.63E-02  4.29E-02        5.15E-03   5.15E-03
Muscle                     0.00E000  2.66E-02  1.63E-02  4.29E-02        0.00E000   1.07E-04
Ovaries                    0.00E000  2.66E-02  2.17E-02  4.82E-02        1.21E-02   9.65E-03
Pancreas                   0.00E000  3.84E-02  3.51E-02  7.35E-02        4.41E-03   1.84E-04
Red Marrow                 0.00E000  1.82E-02  1.98E-02  3.80E-02        4.56E-03   4.56E-03
Osteogenic Cells           0.00E000  3.26E-02  1.80E-02  5.06E-02        1.52E-03   5.06E-04
Skin                       0.00E000  2.66E-02  1.02E-02  3.67E-02        0.00E000   3.67E-04
Spleen                     0.00E000  1.68E-01  4.66E-02  2.15E-01        1.29E-02   5.38E-04
Testes                     0.00E000  2.66E-02  1.41E-02  4.07E-02        0.00E000   0.00E000
Thymus                     0.00E000  2.66E-02  1.48E-02  4.13E-02        0.00E000   1.03E-04
Thyroid                    0.00E000  2.66E-02  1.38E-02  4.04E-02        1.21E-03   2.02E-03
Urinary Bladder Wall       0.00E000  2.08E-01  3.98E-02  2.48E-01        1.49E-02   1.24E-02
Uterus                     0.00E000  2.66E-02  2.44E-02  5.10E-02        0.00E000   1.27E-04
Total Body                 0.00E000  3.57E-02  1.72E-02  5.29E-02        0.00E000   0.00E000
Effective Dose Equivalent (rem/mCi)                                      1.63E-01
Effective Dose (rem/mCi)                                                            9.53E-02
Number of Disintegrations in Source Organs:
Adrenals                     0.00E000  MBq-h/MBq or uCi-h/uCi
Brain                        0.00E000  MBq-h/MBq or uCi-h/uCi
Breasts                      0.00E000  MBq-h/MBq or uCi-h/uCi
Gallbladder Contents         0.00E000  MBq-h/MBq or uCi-h/uCi
LLI                          0.00E000  MBq-h/MBq or uCi-h/uCi
Small Intestine              0.00E000  MBq-h/MBq or uCi-h/uCi
Stomach                      0.00E000  MBq-h/MBq or uCi-h/uCi
ULI                          0.00E000  MBq-h/MBq or uCi-h/uCi
Heart Contents               0.00E000  MBq-h/MBq or uCi-h/uCi
Heart Wall                   0.00E000  MBq-h/MBq or uCi-h/uCi
Kidneys                      2.66E-01  MBq-h/MBq or uCi-h/uCi
Liver                        1.30E-01  MBq-h/MBq or uCi-h/uCi
Lungs                        0.00E000  MBq-h/MBq or uCi-h/uCi
Muscle                       0.00E000  MBq-h/MBq or uCi-h/uCi
Ovaries                      0.00E000  MBq-h/MBq or uCi-h/uCi
Pancreas                     2.36E-03  MBq-h/MBq or uCi-h/uCi
Red Marrow                   0.00E000  MBq-h/MBq or uCi-h/uCi
Cortical Bone                0.00E000  MBq-h/MBq or uCi-h/uCi
Trabecular Bone              0.00E000  MBq-h/MBq or uCi-h/uCi
Spleen                       2.00E-02  MBq-h/MBq or uCi-h/uCi
Testes                       0.00E000  MBq-h/MBq or uCi-h/uCi
Thymus                       0.00E000  MBq-h/MBq or uCi-h/uCi
Thyroid                      0.00E000  MBq-h/MBq or uCi-h/uCi
Urinary Bladder Contents     4.86E-02  MBq-h/MBq or uCi-h/uCi
Uterus/Uterine Wall          0.00E000  MBq-h/MBq or uCi-h/uCi
Remainder                    1.24E000  MBq-h/MBq or uCi-h/uCi
Target Organ Masses:
Adrenals                     1.63E001 g
Brain                        1.42E003 g
Breasts                      3.51E002 g
Gallbladder Wall             1.05E001 g
LLI Wall                     1.67E002 g
Small Intestine              6.77E002 g
Stomach Wall                 1.58E002 g
ULI Wall                     2.20E002 g
Heart Wall                   3.16E002 g
Kidneys                      2.99E002 g
Liver                        1.91E003 g
Lungs                        1.00E003 g
Muscle                       2.80E004 g
Ovaries                      8.71E000 g
Pancreas                     9.43E001 g
Red Marrow                   1.12E003 g
Osteogenic Cells             1.20E002 g
Skin                         3.01E003 g
Spleen                       1.83E002 g
Testes                       3.91E001 g
Thymus                       2.09E001 g
Thyroid                      2.07E001 g
Urinary Bladder Wall         4.76E001 g
Uterus                       7.90E001 g
Total Body                   7.37E004 g
* Mass modified by user
Radiation Weighting Factors:
Alpha:     5.00E00
Beta:      1.00E00
Photon:    1.00E00
** Weighting factor modified by user
